At SalubrisBio, our mission is to develop first-in-class biologics that improve the health and quality of life for people living with complicated diseases.
We have the passion, commitment, and expertise needed to drive our assets through all phases of clinical development to deliver novel biologic therapies to patients.
SalubrisBio is the first company in the world to bring a bispecific antibody into clinical trials in a cardiovascular indication. We endeavor to make this the first of many global innovation achievements.
Chief Executive Officer
Sam is currently CEO of SalubrisBio and has worked at SalubrisBio since 2017. Prior to joining SalubrisBio, Sam worked for more than ten years in strategy consulting and transaction advisory services across several global firms, most recently as a Senior Principal at IMS (now IQVIA). Sam’s commercial strategy engagements encompassed 18 of the top 25 pharmaceutical companies, as well as numerous small and mid-sized biotech companies, with an emphasis on business development and market access. Sam completed his PhD in Virology at the University of Pennsylvania and his Post-Doctoral Fellowship in Gene Therapy and Translational Medicine at Children’s Hospital of Philadelphia. Sam currently also serves as Chairman of the Board at GO Therapeutics, Board Director at MedAlliance SA and Viracta Therapeutics, and a Board Observer at Mercator Medsystems. He is an author of >20 peer-reviewed publications and an inventor on several issued patents.
MD, Chief Medical Officer
Shalabh Singhal, MD, is a board-certified cardiologist with more than a decade of drug development experience. He most recently served as VP and Development Lead at Bristol Myers Squibb, where he led development for multiple products, including SotyktuTM. Previously, he held cardiology positions at Mercer Bucks Cardiology, Community Health Network and Johnson Memorial Hospital. Dr. Singhal holds a Bachelor of Science in Chemistry from Canisius College, and an M.D. from Upstate Medical University. He completed his residency at Thomas Jefferson University and a fellowship at the University of Cincinnati.
Chief Scientific Officer
Jijun Dong, PhD, is a seasoned drug hunter with over a decade of experience in biologics drug discovery and development within the cardiovascular, metabolism, and immune-oncology domains. Prior to joining SalubrisBio, Jijun was the VP of Biologics Research at Xilio Therapeutics, where she focused on complex biologic drug research for immune-oncology indications. She has held positions of increasing responsibility at various companies of different sizes, including Novartis and Alkermes Inc., where she covered activities ranging from early target validation to clinical candidate nomination and IND application. Jijun received her bachelor’s degree in chemistry from Peking University and her PhD in biochemistry from Emory University. She completed her postdoctoral training in Professor Susan Lindquist’s lab at the Whitehead Institute of Biomedical Research, where she studied protein misfolding and its relevance in normal biology, as well as in neurodegenerative diseases.
Interim Chief Financial Officer
Mr. DiPalma is interim Chief Financial Officer and leads all financial and fiscal planning operations for SalubrisBio.
Mr. DiPalma has over 35 years of experience in financial management and capital formation in the life sciences industry. He is currently a managing director of Danforth Advisors, LLC, a financial consultancy that specializes in working with life sciences companies. Prior to and during his tenure at Danforth, Steve has served as Chief Financial Officer to a number of public companies, in addition to many private companies in various stages of development. Immediately prior to joining Danforth in 2014, he served as Chief Financial Officer at Forum Pharmaceuticals from 2009 to 2014. He holds a Bachelor of Science from the University of Massachusetts and a Master in Business Administration from Babson College.
VP of Clinical Development
Amanda McEwen has over 14 years of experience in clinical research that spans work in academia, contract research organizations, and several Boston-area small-to-mid-size biotechnology companies. Throughout her career, Amanda has held roles of increasing responsibility within the Clinical/Regulatory Development space across a range of therapeutic areas including rare, neurodegenerative, respiratory, infectious, and metabolic diseases. Her experience includes a variety of therapeutic product types, including combination products, most notably a novel dry powder inhalation therapy to treat motor issues in Parkinson’s patients, Inbrija™, approved by the FDA and EMA. Amanda has a particular affinity for early phase work and has played pivotal roles in shepherding several programs from the bench to the clinic. In addition to her work in industry, Amanda serves as an adjunct faculty member for Northeastern University’s Master of Science in Regulatory Affairs for Drugs, Biologics, and Medical Devices, specializing in courses on the strategic and technical considerations for IND and NDA/MAA submissions and Pharmacovigilance regulations and best practices. Amanda holds a BA in Psychology from the College of the Holy Cross and a Master of Research Methods in Psychology degree from the University of York.
Dr. Jinhua Feng
Dr. Jinhua Feng joined SalubrisBio in 2017 as the Director of Research and Development. She quickly rose to Vice President, taking charge of analytical and formulation development in-house and outsourcing GMP manufacturing and QC testing. Prior to joining SalubrisBio, Dr. Feng spent more than fifteen years at MedImmune/AstraZeneca, where she concentrated on analytical method development, product characterization and structure/function relationship of monoclonal antibodies and fusion proteins, including Synagis and motavizumab. Her contributions were critical for understanding stabilizing immunoglobulin, photo-induced oxidation, charge variants, and color change of drug products. During her tenure, she also assumed CMC analytical leadership for the production of multiple pipeline programs, including the first monoclonal antibody program transferred to China and the first bispecific ADC program in the company.
Dr. Feng completed her doctorate in Analytical Chemistry from Utah State University and her Post-Doctoral Fellowship at Nebraska Center for Mass Spectrometry.
Naimish Pandya, MD
Oncology Medical Lead
Naimish Pandya, MD, is a board-certified medical oncologist, physician-scientist, and immunotherapy drug developer with more than 17 years of progressive oncology and immuno-oncology clinical development experience. He is former faculty of the University of Maryland Greenebaum Comprehensive Cancer Center, where he led the gastroenterology oncology division and spearheaded multi-specialty-based clinical trials. Subsequently, Dr. Pandya transitioned his career full-time to industry and most recently served as Vice President & Head of Clinical Development at NexImmune, where he oversaw the company’s multi-antigen T cell therapy and progressed products into early clinical development. He previously held senior clinical leadership positions at Northern Biologics and MacroGenics. Dr. Pandya also served in varying roles and leadership at MedImmune/AZ, along with consulting leadership roles at GSK, Incyte and several start-up biotech companies. In these positions, he focused on developing and progressing various IO and targeted therapies, including small molecules, monoclonal antibodies, bispecifics, and oncolytic viruses in both solid tumors and heme malignancies.
Throughout his career, Dr. Pandya has developed oncologic and rheumatologic drug candidates and managed all phases of clinical trials. He has successfully taken many preclinical molecules through an IND launch and developed and executed numerous first-in-human Phase 1 trials. Similarly, he has led multiple global Phase 2 and Phase 3 clinical trials in oncology.
Dr. Pandya received his medical degree from Temple University and completed his oncology training at Thomas Jefferson University in Philadelphia.
Our disease targets are in cardiovascular disease, oncology, and neurodegenerative disease, three leading causes of death in the world today.